Rad Tech CE, ASRT, ARRT® CE, Category A Credits | Radiology Continuing Education

Approvals/Requirements Satisfied by eRADIMAGING Courses

  • ASRT approval for ARRT Category A credit
  • All Courses eligible of international radiographers' CPD requirements
  • ASRT and MDCB are approved continuing education providers of ARRT and all courses are accepted by ARRT
  • California CE requirements met for all radiography courses
  • NMTCB accepted (All Courses)
  • All Courses available for RRAs
  • ARMRIT accepted (All MRI Courses)
  • MDCB approval by the Medical Dosimetrist Certification (Selected Courses)
  • Florida approval for all courses 1 credit or more
  • ARDMS accepted (All Courses)
  • CAMRT and Sonography Canada recognize the ASRT approval (All Courses)
  • Approval: This course is approved by ASRT and MDCB - approved continuing education providers of ARRT.
  • Release Date: 5/11/2020
  • Expiration Date: 5/31/2023
  • Credit Hours: 1 Credit
  • Course Description and objectives:

    Course Description
    Breast cancer is the most common malignancy in American women and the second leading cause of cancer-related mortality. The long-term survival of patients depends critically on the stage at the time of diagnosis. The 5-year survival rate is approximately 99% among patients whose cancer is identified while in situ or local but decreases to less than 25% for those diagnosed with distant metastases. Mammography is widely used in the screening and diagnosis of patients with breast cancer, but it is associated with a high false-positive rate and is less effective in detecting the disease in younger women or in those with dense breast tissue. Functional molecular breast imaging involves the use of nuclear medicine and other techniques to noninvasively visualize, characterize, and quantify biological processes at the cellular and subcellular levels. Molecular imaging techniques may make it possible to visualize breast cancer in earlier stages of disease before the appearance of structural breast lesions become apparent on conventional anatomic imaging. Emerging evidence confirms the utility of molecular imaging in the diagnosis and staging of patients with breast cancer, as well as with predicting and monitoring treatment. New radiotracers and imaging equipment may further enhance the molecular characterization of breast lesions, expanding its range of uses in clinical practice while accelerating the ongoing transition from universal to personal medicine.

    Learning Objectives
    After reading this article, the participant should be able to:

    • EXPLAIN the rationale for functional molecular imaging in the setting of breast cancer.
    • IDENTIFY the different breast-cancer staging and classification systems and their importance in treatment decision-making.
    • COMPARE the indications for the use of gamma-camera imaging and positron emission tomography.
    • APPRAISE the novel radiopharmaceuticals under development and their implications for improved patient assessment and management.

     

    Categories: Mammography, nuclear medicine.

  • CE Information:

    CE Information
    In order to receive CE credit, you must first complete the activity content. When completed, go to the "Take CE Test!" link to access the post-test.

    Submit the completed answers to determine if you have passed the post-test assessment. You must answer 8 out of 10 questions correctly to receive the CE credit. You will have no more than 3 attempts to successfully complete the post-test.

    Participants successfully completing the activity content and passing the post-test will receive 1.0 ARRT Category A credit.

    Approved by the American Society of Radiologic Technologists for ARRT Category A credit.

    Approved by the Medical Dosimetrist Certification Board for MDCB credit.

    Approved by the state of Florida for ARRT Category A credit.

    Texas direct credit.

    This activity may be available in multiple formats or from different sponsors. ARRT does not allow CE activities such as Internet courses, home study programs, or directed readings to be repeated for CE credit in the same biennium.


Breast Cancer: The Role of Functional Molecular Imaging

By Steven Marks*; original text by Mark Bowes, PhD

*President, MedCom Consultants, Inc, Potomac MD; †Medical writer, Portland OR

Address correspondence to: Steven Marks, MedCom Consultants Inc, 1311 Fallsmead Way, Potomac MD 20854. Email: steven.marks52@gmail.com

Disclosure statement: Steven Marks reports having no financial or advisory relationship with any corporate, medical, or political organization doing work related to this paper or other business activity at MedCom Consultants, Inc. Dr Bowes reports having no financial or advisory relationships with corporate organizations related to this activity.  

ABSTRACT

Breast cancer is the most common malignancy in American women and the second leading cause of cancer-related mortality. The long-term survival of patients depends critically on the stage at the time of diagnosis. The 5-year survival rate is approximately 99% among patients whose cancer is identified while in situ or local but decreases to less than 25% for those diagnosed with distant metastases. Mammography is widely used in the screening and diagnosis of patients with breast cancer, but it is associated with a high false-positive rate and is less effective in detecting the disease in younger women or in those with dense breast tissue. Functional molecular breast imaging involves the use of nuclear medicine and other techniques to noninvasively visualize, characterize, and quantify biological processes at the cellular and subcellular levels. Molecular imaging techniques may make it possible to visualize breast cancer in earlier stages of disease before the appearance of structural breast lesions become apparent on conventional anatomic imaging. Emerging evidence confirms the utility of molecular imaging in the diagnosis and staging of patients with breast cancer, as well as with predicting and monitoring treatment. New radiotracers and imaging equipment may further enhance the molecular characterization of breast lesions, expanding its range of uses in clinical practice while accelerating the ongoing transition from universal to personal medicine.

View the full content

Sample eRADIMAGING Course *

* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.

Become a member

Satisfy your CE requirements today!

Join now

We offer special group rates, call or email.

908-253-9001

webmaster@eradimaging.com

Newsletter

Enter your email address to receive our new course alerts.